AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
Provided By GlobeNewswire
Last update: Mar 13, 2025
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
Lausanne, Switzerland, March 13, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the full year ended December 31, 2024, and provided a corporate update.
Read more at globenewswire.com
